A major new study suggests that some older adults taking thyroid medication may no longer need it, challenging the assumption that thyroid treatment is lifelong. The RELEASE trial, a large Dutch clinical study published in 2026, investigated whether adults aged 60 and older could safely reduce or stop levothyroxine, the most commonly prescribed synthetic thyroid hormone replacement. About 1 in 4 participants successfully discontinued their medication after a careful, medically supervised taper, while nearly 75% still required treatment. The findings suggest that thyroid needs can change with age, and what was once necessary may no longer be the right dose or even needed at all .

What Did the RELEASE Trial Actually Find?

Researchers enrolled older adults who had been on a stable levothyroxine dose for at least one year across 58 general practices in the Netherlands. Participants were gradually tapered off their medication using a structured protocol over about a year, with regular check-ins and repeated thyroid function tests at each stage. The results painted a nuanced picture of deprescribing success and limitations .

• Successful Discontinuation: About 25.7% of participants were able to completely stop levothyroxine after the slow, carefully monitored taper without experiencing worsening quality of life.
• Dose Reduction Benefits: Among those who could not stop medication entirely, almost 51% had a reduced dose at final follow-up, which can still reduce risks linked to overtreatment such as heart rhythm problems and bone loss.
• Lower Dose Advantage: People taking 50 micrograms or less had the best chance of stopping, with about 64% able to discontinue medication successfully.
• Continued Need: Nearly 75% of participants could not stop and needed to stay on thyroid medication, demonstrating that for most people, treatment remains essential.

Why Are Experts Cautious About These Results?

While the RELEASE trial offers hope for some patients, researchers and thyroid specialists have raised important concerns about how the study defined success. The study considered people "successful" if their TSH (thyroid-stimulating hormone) remained below 10, even though most doctors and thyroid experts do not consider a TSH of 10 to be evidence of adequate thyroid function. Most laboratories define the upper limit of normal TSH somewhere between 4.0 and 5.5. Using a threshold of 10 means that a substantial proportion of those classified as successful may actually still have mild hypothyroidism, making the true success rate closer to 12 to 13% when stricter standards are applied .

Another major limitation: researchers often did not know why patients were originally prescribed levothyroxine in the first place. Was the patient started on medication for overt hypothyroidism with elevated TSH and obvious symptoms? Did they have autoimmune Hashimoto's thyroiditis? Did they have subclinical hypothyroidism that has since resolved on its own? Did they have a borderline TSH level and nonspecific symptoms? Without this information, deprescribing providers were essentially "working blind," making it difficult to determine who was truly a good candidate for stopping medication .

How to Safely Approach Thyroid Medication Decisions After 60

• Never Stop Abruptly: Deprescribing is not about abruptly stopping medication. It requires a planned, supervised reduction over months, with careful dose reductions and regular lab testing to monitor thyroid function and safety.
• Work With Your Doctor: Any decision to reduce or stop thyroid medication must be made with your healthcare provider, not on your own. This includes multiple doctor visits and lab tests every 6 to 12 weeks to ensure your thyroid levels remain in a safe range.
• Reassess Your Original Diagnosis: Have an honest conversation with your doctor about why you were originally prescribed thyroid medication. Understanding whether you had overt hypothyroidism, autoimmune thyroiditis, or borderline thyroid levels can help determine if deprescribing is appropriate for you.
• Monitor for Symptom Changes: Pay close attention to how you feel during any dose reduction. Thyroid-related symptoms can overlap with aging, sleep issues, heart disease, and depression, making it easy to misinterpret what's causing changes in how you feel.

The key takeaway from the RELEASE trial is not to quit your medication, but to rethink "autopilot" treatment. As we age, thyroid needs can change, and what was once necessary may no longer be the right dose or even needed at all. However, this is not a do-it-yourself project. Stopping thyroid medication requires a slow, medically supervised process with regular lab testing and close attention to symptoms .

Who Might Be a Candidate for Deprescribing?

The RELEASE trial suggests that certain patients may be better candidates for carefully reducing or stopping thyroid medication. People originally diagnosed with mild or borderline thyroid issues, those on lower doses of 50 micrograms or less, and those with unclear reasons for starting medication may have a better chance of successfully discontinuing treatment. However, the study also made clear that the majority of older adults still need thyroid hormone replacement to maintain their health and quality of life .

The practical reality is that deprescribing thyroid medication requires significant time and resources. The RELEASE trial involved multiple doctor visits, lab tests every 6 to 12 weeks, and careful dose reductions over months. This level of monitoring is both difficult and costly to replicate in typical healthcare settings, which means that for many patients, continuing current treatment may remain the most practical option .

If you're over 60 and taking thyroid medication, the message is clear: do not make changes on your own, but do ask your doctor whether your current dose and treatment plan still fit your needs today. A personalized reassessment of your diagnosis, dosage, and current health status can help ensure your thyroid treatment remains appropriate as you age.